Targeting MuRF1 by small molecules in a HFpEF rat model improves myocardial diastolic function and skeletal muscle contractility.

Volker AdamsAntje SchauerAntje AugsteinVirginia KirchhoffRuna DraskowskiAnett JannaschKeita GotoGemma LyallAnita MännelPeggy BarthelNorman MangnerEphraim B WinzerAxel LinkeSiegfried Labeit

Published in: Journal of cachexia, sarcopenia and muscle (2022)

MyoMed-205 improved myocardial diastolic function and prevented SKM atrophy/function in the ZSF1 animal model of HFpEF. Mechanistically, SKM benefited from an attenuated ubiquitin proteasome system and augmented synthesis/activity of proteins of the mitochondrial respiratory chain while the myocardium seemed to benefit from reduced titin modifications and fibrosis.

Keyphrases

left ventricular
skeletal muscle
blood pressure
heart failure
small molecule
type diabetes
cancer therapy
respiratory tract
liver fibrosis